STOCK TITAN

Windtree Therapeutics, Inc. - WINT STOCK NEWS

Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.

Windtree Therapeutics, Inc. (NASDAQ: WINT) is a pioneering biotechnology company specializing in the development of innovative therapies for critical cardiovascular and respiratory conditions. The company's advanced research and proprietary technologies aim to address significant unmet medical needs, offering hope to patients and their families.

At the core of Windtree's portfolio is its KL4 surfactant technology, a synthetic, peptide-containing surfactant structurally similar to human pulmonary surfactant. This technology is being developed for noninvasive administration via aerosolization, with a primary focus on treating Respiratory Distress Syndrome (RDS) in premature infants. The potential of this technology extends to various other respiratory diseases, promising new therapeutic avenues where few or no approved treatments exist.

In the cardiovascular domain, Windtree is advancing istaroxime, a Phase 2 candidate exhibiting unique dual mechanisms that enhance both systolic and diastolic cardiac functions. Istaroxime targets acute heart failure and cardiogenic shock, conditions with high mortality and limited treatment options. Recent collaborations, including a significant license agreement with Lee's Pharmaceutical, aim to develop and commercialize istaroxime in Greater China, reflecting its global potential.

Windtree is also exploring preclinical SERCA2a activators for heart failure, aiming to develop both intravenous and oral formulations to treat acute and chronic heart failure, respectively. Additionally, the company is advancing rostafuroxin, targeting hypertension in patients with specific genetic markers, and a preclinical atypical protein kinase C iota (aPKCi) inhibitor, for potential oncology applications.

Financially, Windtree's strategic licensing and partnerships, such as the recent agreement with Deerfield Management to retire a $15 million liability, have strengthened its balance sheet. The company is strategically positioned to advance its late-stage clinical programs while optimizing its financial resources to support ongoing and future endeavors.

Windtree's commitment to scientific innovation and strategic collaborations is poised to transform treatment paradigms in cardiovascular and respiratory care, with a robust pipeline that holds significant promise for the future.

Rhea-AI Summary
Windtree Therapeutics (NASDAQ:WINT) has announced a significant agreement with Deerfield Management Company to retire a $15 million liability associated with its Aerosurf drug and device combination treatment for premature infants. The company has strengthened its financial position and balance sheet, with no significant debt and increased shareholder equity. Windtree is also targeting Phase 3 readiness in cardiogenic shock with its lead asset istaroxime, which has shown promising results in a phase 2 study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
-
Rhea-AI Summary
Windtree Therapeutics, Inc. has entered into an Exchange and Termination Agreement with Deerfield Management Company to terminate its rights to receive up to $15,000,000 in development and commercial milestone payments associated with AEROSURF®. In exchange, Windtree will issue 608,272 shares of common stock and pay Deerfield $100,000 in cash. The company also agreed to pay an additional $100,000 upon meeting certain conditions. Windtree's President and CEO, Craig Fraser, expressed appreciation for Deerfield's support and stated that the company has strengthened its balance sheet, reduced cash burn rate, and made progress in clinical trials for its lead asset, istaroxime.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
none
-
Rhea-AI Summary
Windtree Therapeutics Inc. (NASDAQ:WINT) has entered into a license agreement with Lee's Pharmaceutical (HK) Ltd. to develop and commercialize its product candidate istaroxime for acute heart failure and cardiogenic shock in the greater China region. The deal supports Windtree's pipeline treatments for acute heart failure and cardiogenic shock and has the potential to provide financial support for development of treatment to address an unmet need and a growing problem in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Windtree Therapeutics, Inc. has entered into a license agreement with Lee’s Pharmaceutical (HK) Limited for the development and commercialization of istaroxime in Greater China, including for acute heart failure and cardiogenic shock. The agreement also includes the licensing of Windtree’s next-generation SERCA2a activators and rostafuroxin. Lee’s will fund Phase 3 for istaroxime and will be responsible for all development, manufacturing, regulatory, and commercial costs for the covered products in the licensed region. Windtree is entitled to receive up to $138.1 million in payments upon the achievement of certain milestones plus up to low double-digit royalties. The agreement also establishes joint committees to oversee regional development and commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.64%
Tags
none
-
Rhea-AI Summary
Windtree Therapeutics, Inc. (WINT) announced new preclinical data on the Company’s lead product candidate, istaroxime, and another preclinical pipeline drug candidate, CVie-216, showing reductions in ventricular arrythmias in a rat heart model of diabetes with restricted and restored coronary blood flow induced injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.43%
Tags
none
-
Rhea-AI Summary
Windtree Therapeutics, Inc. (NASDAQ:WINT) has started phase 2 SEISMiC Extension Study for istaroxime in early cardiogenic shock treatment, aiming to build on positive SEISMiC study data and facilitate the end-of-phase 2 meeting with the FDA. Cardiogenic shock has a high mortality rate and unmet need for drug treatment. Market research shows the potential for istaroxime, with 84% of cardiologists willing to use it. Istaroxime has already shown positive results in treating cardiogenic shock, and the SEISMiC Extension Study is expected to pave the way for a phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
Rhea-AI Summary
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced the enrollment of the first subject in its Phase 2 SEISMiC Extension Study of istaroxime in the treatment of early cardiogenic shock. The study results are expected in mid-2024. The company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime in cardiogenic shock targeting data in a similar timeframe. This extension study aims to evaluate a longer dosing cycle of istaroxime and gather data to characterize the potential benefits of SERCA2a activation in these patients, advancing the company’s clinical and regulatory position for potential Phase 3 readiness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced the granting of Patent No. 3805243 by the European Patent Office, providing coverage for the pure SERCA2a Activator class of drug candidates. These activators are intended for the treatment of heart failure and are devoid of action on the Na+/K+ pump. The new patent provides protection until October 9, 2039 for compounds with the pure SERCA2a mechanism of action. This development is significant for the chronic out-patient and hospital markets, with the potential to benefit nearly half of the chronic heart failure patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
none
-
Rhea-AI Summary
Windtree Therapeutics, Inc. (WINT) reported financial results for Q3 2023, including a net loss of $4.4 million. The company made progress with the istaroxime program and next-generation SERCA2a activators, and announced a new composition of matter patent. Cash and cash equivalents as of September 30, 2023, were $7.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
Rhea-AI Summary
Windtree Therapeutics, Inc. (WINT) to present corporate update at Sidoti Micro Cap Conference, offering virtual 1x1 meetings with investors. Craig Fraser, President and CEO, to speak on late-stage interventions for cardiovascular disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
conferences

FAQ

What is the current stock price of Windtree Therapeutics (WINT)?

The current stock price of Windtree Therapeutics (WINT) is $0.4751 as of November 15, 2024.

What is the market cap of Windtree Therapeutics (WINT)?

The market cap of Windtree Therapeutics (WINT) is approximately 4.2M.

What is Windtree Therapeutics' primary focus?

Windtree Therapeutics focuses on developing innovative therapies for critical cardiovascular and respiratory conditions.

What is the KL4 surfactant technology?

KL4 surfactant technology is a synthetic, peptide-containing surfactant structurally similar to human pulmonary surfactant, aimed at treating respiratory diseases, including RDS in premature infants.

What is istaroxime?

Istaroxime is a Phase 2 candidate developed by Windtree Therapeutics to treat acute heart failure and cardiogenic shock by improving both systolic and diastolic cardiac functions.

What recent partnership has Windtree Therapeutics engaged in?

Windtree Therapeutics has entered a significant partnership with Lee's Pharmaceutical to develop and commercialize istaroxime in Greater China.

What is rostafuroxin?

Rostafuroxin is a drug candidate targeting hypertension in patients with specific genetic profiles, currently under development by Windtree Therapeutics.

How has Windtree Therapeutics strengthened its financial position?

Windtree has strengthened its financial position through strategic licensing agreements and partnerships, such as retiring a $15 million liability with Deerfield Management.

What are SERCA2a activators?

SERCA2a activators are compounds developed by Windtree that enhance cardiac function and are being explored for both intravenous and oral treatments for heart failure.

What is the potential market impact of istaroxime?

If approved, istaroxime could become a standard treatment for improving blood pressure and heart function in patients with acute heart failure and cardiogenic shock.

What is Windtree's approach to oncology?

Windtree is developing a preclinical atypical protein kinase C iota (aPKCi) inhibitor for potential applications in rare and broad oncology indications.

Where can I find more detailed financial information about Windtree Therapeutics?

Detailed financial information can be found in Windtree's Annual Report on Form 10-K and other filings available at www.sec.gov.

Windtree Therapeutics, Inc.

Nasdaq:WINT

WINT Rankings

WINT Stock Data

4.15M
8.75M
0.27%
0.6%
1.32%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WARRINGTON